“ANSTO is closely associated with the 12th Congress of World Federation of Nuclear Medicine and Biology because of our diverse contribution as a member of the nuclear medicine community,” CEO of ANSTO, Dr Adi Paterson said.
“It is a watershed moment for nuclear medicine in general with the development of advanced diagnostic imaging technologies and therapeutic techniques and for ANSTO as an applied research centre and supplier of nuclear medicine products and services.”
A broad cross section of more than 2000 professionals from the medical and scientific community are attending the global event being held in Melbourne, 20-24 April 2018.
Prior to the start of the Congress, delegates had the opportunity to tour ANSTO’s state-of-the art OPAL multipurpose reactor, which produces the world’s most commonly used nuclear diagnostic agent, Molybdenum-99 (the parent isotope of Technetium-99m), and the Australian Synchrotron, which operates the Imaging and Medical beamline with the world’s widest synchrotron X-ray beam.
Dr Paterson said it is critically important that we continue to harness the huge potential of nuclear and accelerator technologies in research, development and production to benefit human health.
“The latest nuclear medicines represent exciting advances because they can combine diagnosis, disease progression monitoring and treatment,” Dr Paterson said.
“ANSTO currently supports a number of clinical trials, which are testing promising new treatments for prostate and pancreatic cancer, neuroendocrine tumours and childhood cancers.
“Although we are not a clinical centre, ANSTO is proud to be contribute and working collaboratively with our partners to deliver better health outcomes for Australians and people around the world.”
First published by the Australian Nuclear Science and Technology Organisation